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Abstract In NSCLC, second-line chemotherapy using
pemetrexed or docetaxel has limited efficacy and should be
dedicated to selected groups of patients. Pemetrexed is an
antifolate compound with the ability to inhibit enzymes (TS,
DHFR and GARFT) involved in pyrimidine and purine syn-
thesis. The objective of this study was to evaluate the associ-
ation between polymorphisms of TS and MHFR genes and
clinical outcomes in NSCLC patients treated with pemetrexed
monotherapy. DNAwas isolated from peripheral blood of 72
non-squamous NSCLC patients treated with pemetrexed.
Using PCR and RFLP methods, the variable number of tan-
dem repeats (VNTR), the G > C SNP in these repeats and
insertion/deletion polymorphism of TS gene as well as
677C > T SNP inMTHFR gene were analyzed and correlated
with disease control rate, progression-free survival and overall
survival (OS) of NSCLC patients. Carriers of 2R/3R(G),
3R(C)/3R(G), 3R(G)/3R(G) genotypes showed significantly
more frequent early progression than carriers of 2R/2R, 2R/
3R(C), 3R(C)/3R(C) genotypes of TS gene (p < 0.05). Among
carriers of triple 28 bp tandem repeats (3R) in TS gene and C/
C genotype of MTHFR gene a significantly shorter OS was
observed (HR = 3.07; p = 0.003). In multivariate analysis,
significantly higher risk of death was observed in carriers of
both 3R/3R genotype in TS and C/C genotype in 677C > T
SNP inMTHFR (HR = 3.85; p < 0.005) as well as in patients
with short duration of response to first-line chemotherapy
(HR = 2.09; p < 0.005). Results of our study suggested that
genetic factors may have a high predictive and prognostic
value (even greater than clinical factors) for patients treated
with pemetrexed monotherapy.
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Introduction
Lung cancer is the most prevalent cause of death due to ma-
lignancies worldwide. There is very low percentage of early
diagnosed NSCLC patients which results in only 15% chance
of surgical resection [1]. Systemic therapy (chemo- and
radiotherapy) is considered to be the main form of lung cancer
treatment. Unfortunately, first-line treatment is of low effec-
tiveness and progression is observed in the vast majority of
patients.
Pemetrexed is one of the novel 3rd generation drugs with
the least side effects reported. In the first-line study, cisplatin
with pemetrexed proved to be more effective in non-
* Paweł Krawczyk
krapa@poczta.onet.pl
1 Department of Pneumonology, Oncology and Allergology, Medical
University of Lublin, Jaczewskiego 8, 20-954 Lublin, Poland
2 Postgraduate School of Molecular Medicine, Warsaw Medical
University, Żwirki i Wigury 61, 02-091 Warszawa, Poland
3 Department of Lung and Chest Cancer, Oncology Centre-Institute,
M. Sklodowska-Curie in Warsaw, W. K. Roentgena 5,
02-781 Warszawa, Poland
4 Greater Poland Center of Pulmonology and Thoracic Surgery of
Eugenia and Janusz Zeyland, Poznań, Poland
5 Department of Clinical Oncology, Chair of Cardio-Thoracic Surgery,
University of Medical Sciences, Szamarzewskiego 82/84,
60-569 Poznań, Poland
6 Regional Centre of Oncology in Łódź, Ignacego Paderewskiego 4,
90-993 Łódź, Poland
7 Institute of Agricultural Medicine of Lublin, Kazimierza
Jaczewskiego 2, 20-950 Lublin, Poland
Pathol. Oncol. Res. (2016) 22:49–56
DOI 10.1007/s12253-015-9966-z
squamous histology of NSCLC and as a result it was regis-
tered in only such histology of lung cancer [2]. Second-line
treatment with pemetrexed monotherapy is possible in non-
squamous patients with good performance status who
progressed after non-pemetrexed first-line chemotherapy,
which was proven by a comparative study with docetaxel [3].
Pemetrexed, a multitarget antifolate, is effective in non-
squamous NSCLC and malignant pleural mesothelioma, with
the main focus on inhibition of enzymes involved in pyrimi-
dine and purine synthesis such as thymidylate synthase (TS),
dihydrofolate reductase (DHFR) and glycinamide ribonucle-
otide formyltransferase (GARFT). TS catalyzes transforma-
tion of dUMP into dTMP. Decreased levels of dTMP results
in inhibition of DNA repair and synthesis, thus cell death
[2–4].
Studies have shown that expression levels of pemetrexed
target enzymesmay alter the effectiveness of the drug [5, 6, 7].
Squamous cell carcinoma was shown to have higher expres-
sion of TS than adenocarcinoma, thus being more resistant to
pemetrexed treatment [8, 9].
Free circulating folates may regulate pemetrexed targets’
activity. Increased level of methyltetrahydrofolate (5-
methylTHF) is a result of changes in the activity of 5,10-
methylenetetrahydrofolate reductase (MTHFR), which results
in higher TS activity and thus reduces pemetrexed efficacy
[10].
There are three well known polymorphic changes that af-
fect TS mRNA level and TS protein expression: various num-
ber of 28-base pair tandem repeats (VNTR) located in the 5′
end untranslated region of TS gene; a single nucleotide poly-
morphism (SNP) G > C in the second repeat of the 28-bp
tandem repeats; and a 6-bp deletion at the 3’ end of the TS
gene (1494del6) [11–13]. Polymorphisms in TS gene are
known to alter effectiveness of 5-fluorouracil (5-FU) in colo-
rectal cancer [14]. Moreover, MTHFR gene polymorphism
677C > T is causing lower expression of MTHFR and de-
creased levels of 5-methylTHF in colon and breast cancer cell
lines [15].
This retrospective, non-randomized, multicenter study was
carried out in order to assess the usefulness of TS andMTHFR
gene polymorphisms as predictive markers in NSCLC pa-
tients treated with pemetrexed monotherapy.
Materials and Methods
The whole studied group consisted of 72 NSCLC patients (46
male, 26 female; median age 61) with non-squamous histolo-
gy, who were treated with pemetrexed monotherapy. Clinical
data was collected from all patients. 500 mg/m2 of pemetrexed
was administered as an intravenous infusion on day 1 of each
21 day cycle. In order to reduce toxicity, patients received folic
acid and B12 vitamin prior to treatment.
The response to chemotherapy was assessed according to
RECIST criteria. The observation period was from 2008 until
February 2014, when progression was observed in 60 patients
of whom 45 died.
The material for the study were blood samples collected in
four oncology centres in Poland. All genetic testing was per-
formed in clinical laboratory in Pneumonology, Oncology and
Allergology Department in Lublin. Venous blood samples of
5 ml have been collected to EDTA-covered tubes. DNA was
extracted using QIAamp DNA Mini Kit (Qiagen, Germany).
The study was approved by the Ethics Committee of the
Medical University in Lublin (No. KE-0254/219/2010).
Genotyping of TS andMTHFR
All studied polymorphism were analysed by polymerase chain
reaction (PCR). Primers used in TS gene VNTR polymorphism
analysis were previously described by Iacopetta et al. [16]. The
analysis of G > C SNP in tandem repeats of TS gene was carried
out using allele-specific PCR (ASP-PCR) with forward primers
designed specifically for G or C nucleotide (5’CGTCCC
GCCGCGCCACTTG 3’ and 5’CGTCCCGCCGCGCCACT
TC 3’, respectively). The reverse primer was the same one used
in the VNTR analysis, described by Iacopetta et al. The ASP-
PCR was carried out in two separate PCR tubes, one for G-
ending primer and one for C-ending primer. The 1494del6 dele-
tion on the 3’ end of TS gene andMTHFR 677C > T SNP were
detected by restriction fragment length polymorphism (RFLP)
technique. Primers used for the detection of 1494del6 were pre-
viously described by Dotor et al. [17], while the MTHFR
677C > T SNP primers were previously described by Frosst
et al. [18]. For the RFLP reaction Fermentas FastDigest DraI
(Thermo Scientific, USA) for TS 1494del6 polymorphism and
Fermentas FastDigest HinfI (Thermo Scientific, USA) for
MTHFR 677C > T SNP restriction enzymes were used. The
digestion process was carried out under the following conditions:
10 min. incubtion in 37° followed by 5 min. digestion in 65°.
Every polymorphism analysis was carried out in the same
reaction mixture of 20 μl, with only PCR primers being
changed specifically for the polymorphism. The mixture
contained: 100 ng of sample DNA, 1 μM of each primer,
0.2 mM of each dNTP, 2.4 mM of MgCl2 and 1 U Taq poly-
merase with 1 × Reaction Buffer (Thermo Scientific, USA).
All reactions were carried out in a Biometra TPersonal
thermocycler (Biometra, Germany).
Products of PCR were visualised on 2 % agarose gel with
ethidium bromide. TS VNTR polymorphism PCR products
differed according to the number of 28 bp repeats. In
Caucasian population the most often described genotypes
consist of two or three repeats: 2R/2R and 3R/3R homozy-
gotes, and 2R/3R heterozygotes. 2R/2R homozygotes pro-
duce a 116 bp band on the gel, 3R/3R homozygotes produce
a 144 bp band, and heterozygotes show both bands - 116 and
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144 bp. The ASP-PCR for the G > C SNP in TS gene shows
two band patterns: the common G nucleotide presented three
bands: 124 and 96 bp specific for G-ending primer and 68 bp
band specific for C-ending primer, the rare C nucleotide pre-
sented three bands of 124 bp for G-ending primer and two
bands of 96 and 68 bp for C-ending primer. The reaction
products of G > C SNP are shown in two separate lanes, one
for G-ending primer and one for C-ending primer.
The 6 bp deletion at the 3’ end of TS gene shows two band
types: 142 bp for −6/−6 genotype and 148 bp for +6/+6 bp.
The PCR products digestion with DraI restriction enzyme is
possible only when the insertion genotype is present, so it
creates two smaller bands of 88 and 60 bp. The heterozygous
genotype +6/−6 presents four bands of 148, 142, 88 and
60 bp. The products of PCR for 677C > T SNP in MTHFR
gene present following patterns: 198 bp band for C/C geno-
type and 175 and 23 bp band for T/T genotype when digested
withHinfI restriction enzyme. The C/T heterozygote is present
on the gel as three band of 198, 175 and 23 bp. The smallest
band of 23 bp is not visible on the gel as it is migrating on the
gel with reaction primers.
Statistical Analysis
Yates’ chi-square test was used to assess differences between
categorical variables and deviation from the Hardy-Weinberg
equilibrium. Groups of patients with different clinical and mo-
lecular factors were compared using Kaplan-Meier method, in
order to determine the probability of progression-free survival
(PFS) and overall survival (OS). To determine the influence of
the studied factors on PFS and OS of patients treated with
pemetrexed monotherapy, the Cox regression model with
step-by-step selection was used.
Results
The studied group consisted of NSCLC patients treated with
pemetrexedmonotherapy in second- or third-line and first-line
patients who were not eligible for cisplatin. In this group there
were 24 carriers of double 28 bp tandem repeats (33.3 %), 17
triple repeats (23.6 %), the rest (43.1 %) were heterozygous.
Among the carriers of triple repeats in one or both alleles, the
G nucleotide in the second repeat of 28 bp appeared in 25
patients (34.7 %). The presence of 1494del6 deletion was
observed in 8 patients (11.1 %), there were 28 carriers of
one allele with deletion (38.95 %) and the insertion was pres-
ent in 50 % of patients. Allele T in 677C > T SNP inMTHFR
gene was present in 40 patients (55.6 %) among which there
were 11 T/T homozygous patients (15.3 % of the whole stud-
ied group).
66.7 % of the studied group showed disease control during
pemetrexed monotherapy, of whom only 7 reached partial
response (PR) (9.7 %). In 24 patients (33.3 %) disease pro-
gression was observed during first two months after
pemetrexed monotherapy. Median progression-free survival
reached 4.5 months, while median overall survival reached
9 months.
Surprisingly, among all the analyzed clinical factors, none
has significantly influenced the risk of early disease progres-
sion or progression-free survival. Slightly prolonged overall
survival (HR = 0.58, p = 0.076) was observed among patients
with PFS longer than 6 months after first-line non-pemetrexed
chemotherapy (Table 1).
It was observed that among carriers of triple 28 bp tandem
repeats with G allele in the second tandem repeat, disease
progression was significantly more frequent (p = 0.0287) than
among carriers of other genotype combinations. PFS and OS
were shorter in carriers of such genotype, however these were
not statistically significant differences (Table 2). Only among
carriers of both triple tandem repeats in TS gene and C/C
genotype inMTHFR 677C > T polymorphism, a double short-
ening of PFS may be observed in comparison to carriers of
other genotype combinations. However, this difference was
not statistically significant either (Fig. 1, Table 2).
Carriers of both triple 28 bp tandem repeats in both alleles
of TS gene and C/C genotype in 677C > T SNP in MTHFR
gene had significantly shorter overall survival in comparison
to carriers of other genotype combinations (6.75 vs.
12 months, p = 0.0031) (Fig. 2, Table 2).
Using Cox logistic regression we were unable to create a
model evaluating the power of the impact of the studied clin-
ical and molecular factors on the risk of early progression due
to the lack of significance of each determinant. The model
created for the risk of early death has reached the significance
threshold, however the only variable, which significantly in-
fluenced this risk, was the presence of both triple 28 bp tan-
dem repeats in TS gene and C/C genotype in 677C > T SNP in
MTHFR gene as well as short duration of PFS after first-line
non-pemetrexed chemotherapy (Table 3).
Discussion
In second-line therapy, pemetrexed is administered as mono-
therapy, and this form was registered based on a large-scale,
multicenter, randomized, phase III clinical trial performed on
571 NSCLC patients. The study compared the effectiveness of
second-line pemetrexed or docetaxel monotherapy and it did
not show differences in efficacy of the drugs, however signif-
icantly less toxicity was observed after pemetrexed treatment.
In pemetrexed arm objective response and stable disease was
observed in 71.2 % of the studied group, PFS reached
2.9 months and OS – 8.3 months. The study also revealed that
the basic clinical factors such as good performance status
(PS = 0), locally advanced disease and time since last
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chemotherapy over 3 months are positively influencing over-
all survival in NSCLC patients treated with pemetrexed
monotherapy [3].
Pemetrexed monotherapy was compared with a
pemetrexed/carboplatin regime, in second-line of NSCLC
treatment, in GOIRC 02–2006 clinical trial. PFS in the
pemetrexed arm reached 3.6 months and OS – 8.8 months,
which were similar to the result of the Hanna et al. trial. Two-
drug regime showed slightly higher effectiveness but for a
price of higher toxicity [19].
Maintenance therapy using pemetrexed is possible in se-
lected non-squamous NSCLC patients. The PARAMOUNT
Fig. 2 Impact of TS VNTR
polymorphism and a 677C > T
SNP in MTHFR gene on overall
survival in non-squamous
NSCLC patients treated with
pemetrexed monotherapy
Fig. 1 Impact of TS VNTR
polymorphism and a 677C > T
SNP in MTHFR gene on
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clinical trial showed that pemetrexed monotherapy after suc-
cessful first-line pemetrexed/platinum therapy, extends
progression-free survival to 4.1 months and overall survival
to 13.9 months [20].
In our study, we reached results similar to the ones obtained
by Hanna et al. Median PFS in patients treated with
pemetrexed monotherapy was 4.5 months and OS – 9 months.
Such results were reached even though only 18 % of our
studied group received further treatment lines. Only slight
but not significant differences in OS are visible between pa-
tients with different PS (12.5 vs. 10.5 months for PS = 0 and
PS = 1, respectively), in patients with or without anemia (9.5
vs. 12.5 months) and in patients with long and short response
to first-line non-pemetrexed chemotherapy (12 vs.7 months).
Clinical factors are important in proper qualification to
chemotherapy but it is not always possible to choose the best
option based only on them, thus molecular factors are being
studied more and more intensively in order to find relevant
ones, also in pemetrexed treatment.
The most often studied molecular factor is the expression
of thymidylate synthase. A study on 110 NSCLC patients
treated with pemetrexed in third- or fourth-line did not show
any significant influence of TS expression on PFS or OS.
However it is worth mentioning that the researchers had only
limited access to cancer tissue (only 13 out of 55 samples were
eligible for immunohistochemical analysis) [21].
Analysis of pemetrexed target genes (TS, DHFR, GARFT
and MTHFR) was carried out on 90 adenocarcinoma Asian
patients treated with pemetrexed monotherapy in third- or fur-
ther lines. No relationship was found between the polymor-
phisms and response rates, but it is interesting that carriers of
Bhigh expression^ genotypes in TS gene (2R/3R(G), 3R(C)/
3R(G), 3R(G)/3R(G)) reached longer PFS (5.2 vs. 3.7months)
and OS (31.8 vs. 18.5 months) than carriers of Blow
expression^ genotypes (2R/2R, 2R/3R(C), 3R(C)/3R(C)),
which is in contradiction to the results from the studies of
the same polymorphism but in first-line pemetrexed treatment
[22].
Smit et al. carried out a comparison of pemetrexed mono-
therapy with pemetrexed/carboplatin regime in second-line
treatment of NSCLC patients. As a part of the study a phar-
macogenetic analysis was carried out. There was no connec-
tion between Blow/high expression^ genotypes of TS gene and
treatment results, but a significant correlation was observed in
carriers of T/T genotype ofMTHFR 677C > T polymorphism,
where PFS was longer for such patients when compared to
carriers of other genotypes (7.9 vs. 2.9 months; p = 0.003)
[23].
The analysis of two clinical trials: GOIRC 02–2006 (19) and
NVALT-7 (23), for polymorphisms connected with pemetrexed
effectiveness, showed that T/T genotype of MTHFR 677C > T
polymorphism is correlatedwith longer PFS (5.4 vs.3.4months;
p = 0.012) and OS (16.4 vs. 8.5 months; p = 0.026) when
compared to other genotypes (C/C and C/T) [24].
In our study carriers of Bhigh expression^ genotypes in TS
gene showed significantly more frequent early progression
than carriers of Blow expression^ genotypes. Small (but not
statistically significant) differences in OS were observed
among carriers of different genotypes of MTHFR gene
677C > T polymorphism (17.5 vs. 11 months for carriers of
T/T and C/C + C/T, respectively). Among carriers of 3R/3R
genotype in TS gene and C/C genotype ofMTHFR 677C > T
polymorphism a significantly shorter OS was observed (6.75
vs. 12months for carriers of 3R/3R + C/C and carriers of other
genotype combinations respectively; p = 0.0031). Moreover,
in multivariate analysis, significantly higher risk of death was
observed in carriers of both 3R/3R genotype in TS gene and C/
C genotype in 677C > T SNP in MTHFR gene as well as in
patients with short PFS after first-line non-pemetrexed chemo-
therapy. These results are in line with other studies, where the
presence of 3R/3R genotype in TS gene and C/C genotype in
MTHFR gene where considered negative predictive factor in
pemetrexed therapy.
Molecular factors become more meaningful when consider-
ing a relevant treatment option for cancer patients. Studies carried
out on first-line pemetrexed/platinum treated patients seem to
confirm usefulness of some factors such as thymidylate synthase
expression, but in pemetrexed monotherapy group there is still
very little relevant information. It is also worth mentioning that
patients who receive second or further lines of chemotherapy
usually have worse prognosis than those who are treated with
first-line. Therefore, based on our study, it appears that the stud-
ied genetic factorsmay have high predictive and prognostic value
(as high as clinical factors). Our results show that analysis of
VNTR polymorphism in TS gene, an inside G > C SNP in
VNTRs and MTHFR gene 677C > T SNP might help in
selecting a group of non-squamous NSCLC patients who will
benefit significantly from pemetrexed monotherapy, but in order
Table 3 Multivariate Cox logistic regression model of factors affecting the overall survival of non-squamousNSCLC patients treated with pemetrexed
monotherapy
β p HR [95%CI]
C/C genotype ofMTHFR SNP 677C > T + 3R/3R genotype of TS gene 1.3469 0.0042 3.8456 [1.5364–9.6256]
Short duration of PFS after first-line no-pemetrexed chemotherapy (<6 months) 0.7385 0.00299 2.0928 [1.0782–4.0622]
Overall fit model: p = 0.00082, χ2 = 9.606
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to evaluate properly the usefulness of the chosen molecular fac-
tors more large-scale and prospective studies on more represen-
tative groups are needed.
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